Latest HSIC news

Here's Why Henry Schein (HSIC) is a Strong Growth Stock

Zacks Investment Research · Mon, 21 Sep 2026 10:46:05 -0400

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Henry Schein Still Gives Me A Reason To Smile After This Nice Move Higher

Seeking Alpha · Sat, 19 Sep 2026 06:19:05 -0400

Henry Schein remains a dominant global provider of dental and medical practitioner supplies, with recent share price outperformance versus the S&P 500. HSIC delivered strong Q2 results: revenue up 6.7% to $3.46B, net income and cash flow both meaningfully improved, and all business segments showed growth. Management raised 2026 guidance, now expecting 4.5–5.5% revenue growth and adjusted EPS of $5.29–$5.39, reflecting ongoing operational momentum.

Are Investors Undervaluing Henry Schein (HSIC) Right Now?

Zacks Investment Research · Fri, 18 Sep 2026 10:41:04 -0400

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

What Makes Henry Schein (HSIC) a New Buy Stock

Zacks Investment Research · Wed, 16 Sep 2026 13:01:04 -0400

Henry Schein (HSIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

HSIC or SAUHY: Which Is the Better Value Stock Right Now?

Zacks Investment Research · Wed, 16 Sep 2026 12:40:55 -0400

Investors interested in Medical - Dental Supplies stocks are likely familiar with Henry Schein (HSIC) and Straumann Holding AG (SAUHY). But which of these two stocks offers value investors a better bang for their buck right now?

Here's Why Henry Schein (HSIC) is a Strong Value Stock

Zacks Investment Research · Wed, 16 Sep 2026 10:41:09 -0400

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Henry Schein: Growth Is Improving, But The Valuation Stays Cheap

Seeking Alpha · Wed, 16 Sep 2026 10:09:02 -0400

Henry Schein is rated buy with a 12-month price target of $104, reflecting accelerating organic growth, margin expansion, and substantial share repurchases. Q2 2026 results showed 4.6% internal growth, 48 bps gross margin expansion, and a 6.7% reduction in diluted share count, signaling improved business quality. The BOLD+1 cost program targets $125M+ in annual run-rate operating income gains by end-2026, supporting double-digit earnings growth potential into 2027.

Market information is provided for research and visualization and is not investment advice.